Overview
- Phase 1b in moderate to severe eczema enrolled 22 patients for four weeks and nearly eliminated STAT6, showing about 98% reduction in blood and 94% in skin with symptom and biomarker improvements and a favorable safety profile.
- Shares surged more than 40% to a record high on the update, lifting 2025 gains to roughly 140%.
- The eczema Phase 2b trial is underway with topline results targeted by mid-2027, and an asthma Phase 2b is slated to begin in the first quarter of 2026.
- KT-621 is an oral degrader of STAT6, a protein central to Type‑2 inflammation implicated in eczema and asthma.
- Coverage notes a roughly $4.8 billion market value, about $979 million in cash with runway into the second half of 2028, and a newly announced $500 million equity offering that could rise to $575 million with a $75 million overallotment option.